Evaluation of ICI sensitivity for pembrolizumab in combination with anti-platelet therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC).

Authors

Karthik Chakravarthy

The Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Karthik Chakravarthy , John M. Kaczmar , Brian Riesenberg , Carolyn D. Britten , Alan Brisendine , Elizabeth Goodwin Hill , Bei Liu , Zihai Li

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.

First Author: Douglas Adkins

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Use of cetuximab added to weekly chemotherapy to improve progression-free survival in patients with recurrent metastatic head and neck squamous cell carcinoma after progression on immune checkpoint inhibitors.

First Author: Majd Issa

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.

First Author: A. Dimitrios Dimitrios Colevas

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Efficacy from the ongoing phase I trial Study 1100 with NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with locoregionally recurrent or metastatic HNSCC.

First Author: Colette Shen